Home parenteral nutrition in adults: a multicentre surveyin Europe in 1993

Gossum, A. Van; Bakker, H.; Francesco, Antonella De; Ladefoged, K.; León‐Sanz, Miguel; Messing, Bernard; Pironi, Loris; Pertkiewicz, M.; Shaffer, Jon; Thul, P.; Wood, S

doi:10.1016/s0261-5614(96)80019-7

Cited by 113 publications

(45 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, there are very few data to be compared with those which were observed in this study. In the European countries, the point prevalence of HPN has been reported to range between 5 and 49 cases per million inhabitants [3], with a percentage of patients having a malignant disease ranging from 5 to 60% [4]. Therefore, the prevalence of HPN for CIF due to benign disease has been estimated to range from 5 to 20 Fig.…”

Section: Discussionmentioning

confidence: 99%

“…On the contrary, the use of HEN in oncological patients was approximately twice that of the UK. The Italian attitude towards the use of HPN in the context of palliative care for cancer patients has been well recognised since the first European survey on HPN in 1993 [4]. Another reason could be the more frequent use of a central venous catheter previously positioned for chemotherapy for HPN instead of activating enteral tube feeding.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development of home artificial nutrition in Italy over a seven year period: 2005–2012

Pironi

2017

BMC Nutr

View full text Add to dashboard Cite

Background: In 2005, the Italian Society for Artificial Nutrition and Metabolism carried out a national survey on the prevalence of home artificial nutrition (HAN), enteral (HEN) and parenteral (HPN). A second survey was carried out in 2012 to investigate the development of HAN in Italy. Methods: The Local Health Care Units (LHCUs) were required to record the ongoing cases of HAN using a structured questionnaire. The point prevalence (n./million inhabitants) was analysed according to patient age and disease categories. Data were compared with those obtained in 2005.Results: Data were obtained from 65% of the LHCUs, representing 73% of the Italian population. The prevalence of HAN was 325.5 (90.3% adults, 84.6% HEN). As in 2005, a wide range of prevalence was observed among the administrative regions. The most frequent disease category for HPN was oncological in adults and intestinal failure in children; for HEN, it was neurological in both age groups. A positive correlation was observed between the regional prevalence of HAN and the regional population aging index (p = 0.018). The prevalence of HAN in 2012 was 66% higher than that in 2005. In the individual regions, a negative association was observed between the 2012% prevalence increase of HAN (2012HAN ( :2005 and the HAN prevalence in 2005 (p = 0.020). Conclusions: A two-thirds increase in HAN prevalence was observed over seven years, probably due to improved HAN organisation and management in those regions which showed a low prevalence in 2005. Population aging seemed to be one of the main factors necessitating HAN.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Development of home artificial nutrition in Italy over a seven year period: 2005–2012

Pironi

2017

BMC Nutr

View full text Add to dashboard Cite

show abstract

“…However, in our patients treated for o4 weeks, HPN was provided only as compassionate therapy and mostly for hydrating, more than full PN therapy. HPN registries available from various countries as well as international reports display a quite large difference in terms of patient selection (Mughal and Irving, 1986;Howard et al, 1991Howard et al, , 1995De Francesco et al, 1995;Takagi et al, 1995;Bozzetti et al, 1996;Van Gossum et al, 1996, 1999Faisinger and Gramlich, 1997; Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, 2002; SINPE Executive Committee, 2002b). In particular, cancer cases may represent the largest percentage of HPN patients in some (for example 57% in Italy or 60% in The Netherlands) and the lowest in other countries, that is, 8% in Denmark and 5% in the United Kingdom.…”

Section: Discussionmentioning

confidence: 99%

“…It is clear from the available literature on national registries that HPN in some countries is currently prescribed in terminal cancer patients while this is not the rule in others (Mughal and Irving, 1986;Howard et al, 1991Howard et al, , 1995Van Gossum et al, 1996, 1999. Furthermore, the appropriateness of indications remains a clinical challenge to improve its application, besides other already referred factors, such as local economic, social and cultural influences.…”

Section: Introductionmentioning

confidence: 99%

Adult Home Parenteral Nutrition: a clinical evaluation after a 3-year experience in a Southern European centre

et al. 2005

View full text Add to dashboard Cite

Results: In all, 140 (88%) were cancer and 19 (12%) noncancer patients. Main indications were carcinosis in 68 for total, and hypophagia/dysphagia in 62 patients for partial/integrative (to oral-enteral nutrition) HPN; mean duration of HPN was 81.457110.86 days of treatment and infection rate 2.89% in the whole population and 2.66% in the 36 patients treated for more than 3 months. No other major complications have been observed. Conclusion: HPN is confirmed to be a safe and effective treatment when prescribed and administered by a trained team.

show abstract

“…Since the introduction of HPN in the 1970s, HPN prevalence and incidence have been steadily increasing in Europe, with a large multicentric survey showing an annual incidence of 4-6 per 10 6 inhabitants and a prevalence of 2-40 per 10 6 inhabitants [4][5][6] . The most common indications for long-term HPN in Europe are Crohn's disease, mesenteric vascular disease, cancer and radiation enteritis [7] .…”

Section: Introductionmentioning

confidence: 99%

Management of Home Parenteral Nutrition: A Prospective Multicenter Observational Study

et al. 2015

View full text Add to dashboard Cite

BACKGROUND: There are no specific Swiss home parenteral nutrition (HPN) data showing patient characteristics, quality of life (QoL) and complications. The goal of this study was to collect representative nationwide data on current adult HPN patients in Switzerland for international comparability and benchmarking. METHODS: This was a multicenter, nationwide, observational study. We conducted interviews for demographics, PN characteristics, QoL and complications. The data were assessed at baseline and after a follow-up of 3 months using a questionnaire. RESULTS: Thirty-three adult patients were included. The most common underlying diseases were cancer, radiation enteritis and state after bariatric surgery, and the most prevalent indication was short bowel syndrome. During the 3-month observation period, significant increase or stabilization of body weight occurred in the patients, physical activity scores improved from 34.0 to 39.4 and mental scores improved from 41.9 to 46.4. HPN dependency and traveling restrictions were of the greatest concern. Diarrhea, xerostomia and/or thirst were frequent complaints. CONCLUSION: Anthropometric parameters and QoL improved during the observational period in this HPN cohort. These Swiss HPN data are prerequisite for evaluation and comparison of HPN recommendations and best clinical practice, status of professional care instructions related to HPN effectiveness, quality of treatment and patient safety.

show abstract

Home parenteral nutrition in adults: a multicentre surveyin Europe in 1993

Cited by 113 publications

References 17 publications

Development of home artificial nutrition in Italy over a seven year period: 2005–2012

Development of home artificial nutrition in Italy over a seven year period: 2005–2012

Adult Home Parenteral Nutrition: a clinical evaluation after a 3-year experience in a Southern European centre

Management of Home Parenteral Nutrition: A Prospective Multicenter Observational Study

Contact Info

Product

Resources

About